scispace - formally typeset
R

Roberta Maggio

Researcher at Sapienza University of Rome

Publications -  30
Citations -  1240

Roberta Maggio is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Chronic lymphocytic leukemia & Leukemia. The author has an hindex of 12, co-authored 29 publications receiving 1015 citations. Previous affiliations of Roberta Maggio include Imperial College London.

Papers
More filters
Journal ArticleDOI

HaCaT Cells as a Reliable In Vitro Differentiation Model to Dissect the Inflammatory/Repair Response of Human Keratinocytes

TL;DR: HaCaT cells, a long-lived, spontaneously immortalized human keratinocyte line which is able to differentiate in vitro, is investigated as a suitable model to follow the release of inflammatory and repair mediators in response to TNFα or IL-1β to highlight that Ca2+ concentration in the medium, cell density, and presence of serum influences at different levels therelease of proinflammatory mediators by HaCaT Cells.
Journal ArticleDOI

BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells

TL;DR: A differential genotypic and functional response to BCR ligation between IgV(H) M and UM cases is operational in CLL, indicating that response to antigenic stimulation plays a pivotal role in disease progression.
Journal ArticleDOI

Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases

TL;DR: Microarray analysis of CLL cells showed a distinctive genomic profile with an overrepresentation of BCR-related and ribosomal genes, regulators of signal transduction and transcription, which suggests that BCR signaling may play an important role in this scenario as the most significant feature of the leukemic clone in regression.
Journal ArticleDOI

Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission

TL;DR: These findings document for the first time the possibility of expanding ex vivo cytotoxic effectors with autologous killing capacity from ALL patients in remission, and suggest a new potential immunotherapeutic strategy for the management of early disease recurrence or of residual disease.